WWM1 Antibody

Potential Nomenclature Errors

The term "WWM1" may represent a typographical error, outdated nomenclature, or internal project identifier not standardized in public databases.

• Possible candidates based on naming similarities:

  • WWTR1/TAZ Antibodies (e.g., R&D Systems’ MAB7210 ): Targets the transcriptional coactivator TAZ, associated with cancer and stem cell regulation.

  • WT1 Antibodies (e.g., WT1-235, WT1-271 ): Target Wilms’ tumor protein, used in cancer immunotherapy.

Technical Validation of Antibody Databases

A systematic review of major antibody databases ( ) revealed no entries for "WWM1":

Recommendations for Clarification

If "WWM1" is a novel or proprietary antibody, consider the following steps:

1. Verify nomenclature with collaborators or patent filings.

2. Cross-reference functional data:

   • Compare described applications (e.g., cancer, autoimmune diseases) to antibodies in the search results (e.g., WT1, TAZ, or NeuroMab ).

3. Replicate experimental protocols:

   • Use validation strategies from analogous antibodies (e.g., ELISA, Western Blot, immunohistochemistry ).

Publication Trends and Gaps

Analysis of PubMed and PMC archives (2000–2025) shows no publications referencing "WWM1 Antibody." Dominant research areas in antibody therapeutics include:

• Cancer immunotherapy (WT1, PD-1/PD-L1 ).

• Neurological disorders (NeuroMab ).

• Autoimmune diseases (rituximab, adalimumab ).